{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:36:08Z","timestamp":1785267368468,"version":"3.55.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Novel hormonal therapy (NHT) agents have been shown to prolong overall survival in numerous randomized clinical trials for patients with advanced prostate cancer (PCa). There is a paucity of data regarding the pattern of use of these agents in patients from different racial and ethnic groups.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess racial and ethnic disparities in the use of NHT in patients with advanced PCa.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study comprised all men diagnosed with de novo advanced PCa (distant metastatic [M1], regional [N1M0], and high-risk localized [N0M0] per Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy [STAMPEDE] trial criteria) with Medicare Part A, B, and D coverage between January 1, 2011, and December 31, 2017, in a Surveillance, Epidemiology, and End Results (SEER)\u2013Medicare linked database including prescription drug records. Data analysis took place from January through May 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Race and ethnicity (Black [non-Hispanic], Hispanic, White, or other [Alaska Native, American Indian, Asian, Pacific Islander, or not otherwise specified and unknown]) abstracted from the SEER data fields.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was receipt of an NHT agent (abiraterone, enzalutamide, apalutamide, or darolutamide) using a time-to-event approach.<\/jats:p><\/jats:sec>Results<\/jats:title>The study included 3748 men (median age, 75 years [IQR, 70-81 years]). A total of 312 (8%) were Black; 263 (7%), Hispanic; 2923 (78%), White; and 250 (7%) other race and ethnicity. The majority of patients had M1 disease (2135 [57%]) followed by high-risk N0M0 (1095 [29%]) and N1M0 (518 [14%]) disease. Overall, 1358 patients (36%) received at least 1 administration of NHT. White patients had the highest 2-year NHT utilization rate (27%; 95% CI, 25%-28%) followed by Hispanic patients (25%; 95% CI, 20%-31%) and patients with other race or ethnicity (23%; 95% CI, 18%-29%), with Black patients having the lowest rate (20%; 95% CI, 16%-25%). Black patients had significantly lower use of NHT compared with White patients, which persisted at 5 years (37% [95% CI, 31%-43%] vs 44% [95% CI, 42%-46%]; P<\/jats:italic>\u2009=\u2009.02) and beyond. However, there was no significant difference between White patients and Hispanic patients or patients with other race or ethnicity in NHT utilization (eg, 5 years: Hispanic patients, 38% [95% CI, 32%-46%]; patients with other race and ethnicity: 41% [95% CI, 35%-49%]). Trends of lower utilization among Black patients persisted in the patients with M1 disease (eg, vs White patients at 5 years: 51% [95% CI, 44%-59%] vs 55% [95% CI, 53%-58%]). After adjusting for patient, disease, and sociodemographic factors in multivariable analysis, Black patients continued to have a significantly lower likelihood of NHT initiation (adjusted subdistribution hazard ratio, 0.76; 95% CI, 0.61-0.94, P<\/jats:italic>\u2009=\u2009.01).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of Medicare beneficiaries with advanced PCa, receipt of NHT agents was not uniform by race, with decreased use observed in Black patients compared with the other racial and ethnic groups, likely due to multifactorial obstacles. Future studies are needed to identify strategies to address the disparities in the use of these survival-prolonging therapies in Black patients.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.45906","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:31:12Z","timestamp":1701448272000},"page":"e2345906","source":"Crossref","is-referenced-by-count":23,"title":["Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Ting Martin","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Mahal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Barragan-Carrillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spratt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Division of Hematology and Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca F.","family":"Valle","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Garraway","sequence":"additional","affiliation":[{"name":"Department of Urology, UCLA, Los Angeles, California"},{"name":"Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, California"},{"name":"Division of Urology, VA Greater Los Angeles Healthcare System, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Vapiwala","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles (UCLA), Los Angeles"},{"name":"Department of Urology, UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"issue":"1","key":"zoi231337r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"zoi231337r3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer.","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"issue":"21","key":"zoi231337r4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi231337r5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"zoi231337r6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer.","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi231337r7","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer.","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"zoi231337r8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi231337r9","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1200\/JCO.2021.39.15_suppl.5073","article-title":"Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis.","volume":"39","author":"Freedland","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi231337r10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy.","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231337r11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.v66.4","article-title":"Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities.","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"zoi231337r12","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.v128.21","article-title":"Racial disparities in Black men with prostate cancer: a literature review.","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"zoi231337r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11869","article-title":"Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality.","volume":"5","author":"Burgess","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi231337r14","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.2105\/AJPH.2015.302903","article-title":"Implicit racial\/ethnic bias among health care professionals and its influence on health care outcomes: a systematic review.","volume":"105","author":"Hall","year":"2015","journal-title":"Am J Public Health"},{"issue":"16","key":"zoi231337r15","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1073\/pnas.1516047113","article-title":"Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between Blacks and Whites.","volume":"113","author":"Hoffman","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi231337r2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Accessed April 1, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2812415\/ma_2023_oi_231337_1700596721.57489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T16:31:15Z","timestamp":1701448275000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2812415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.45906","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}